81 related articles for article (PubMed ID: 15385819)
1. A histopathologic screening method for rational use of organs from prostate-specific antigen-positive multiorgan donors: the Italian Emilia-Romagna Region experience.
D'Errico Grigioni A; Corti B; Fiorentino M; Pirini MG; Ridolfi L; Venturoli N; Grigioni WF;
Transplantation; 2004 Sep; 78(6):941-4. PubMed ID: 15385819
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of prostate cancer staging in organ donors: intraoperative histology on periglandular soft tissues-a proposal.
Avellini C; Baccarani U; Orsaria M; Adani GL; Bresadola V; Lorenzin D; Bresadola F; Beltrami CA
Transplant Proc; 2009 May; 41(4):1099-103. PubMed ID: 19460491
[TBL] [Abstract][Full Text] [Related]
3. A multiorgan donor cancer screening protocol: the Italian Emilia-Romagna region experience.
Fiorentino M; D'Errico A; Corti B; Casanova S; Ridolfi L; Venturoli N; Sestigiani E; Grigioni WF
Transplantation; 2003 Dec; 76(12):1695-9. PubMed ID: 14688518
[TBL] [Abstract][Full Text] [Related]
4. Prostate-Specific Antigen: Nonspecific in Deceased Organ Donors.
Pabisiak K; Ostrowski M; Kram A; Safranow K; Myślak M; Sieńko J; Sulikowski T; Ciechanowski K
Transplant Proc; 2016 Jun; 48(5):1374-7. PubMed ID: 27496408
[TBL] [Abstract][Full Text] [Related]
5. Prostate Specific Antigen-Positive Deceased Organ Donor: A Pathologist Is Indispensable.
Pabisiak K; Ostrowski M; Kram A; Safranow K; Słojewski M; Ciechanowski K
Transplant Proc; 2016 Sep; 48(7):2450-2453. PubMed ID: 27742319
[TBL] [Abstract][Full Text] [Related]
6. Importance of tumoral markers in donors: study of prostate-specific antigen.
González-Segura C; Pascual M; Cañizares R; García-Huete L; Torras J; Riera L; Condom E
Transplant Proc; 2003 Aug; 35(5):1647-9. PubMed ID: 12962743
[TBL] [Abstract][Full Text] [Related]
7. The Italian multiorgan donor cancer screening protocol: 2002-2005 experience.
Zucchini N; Fiorentino M; D'Errico Grigioni A; Rizzato L; Venettoni S; Nanni Costa A; Grigioni WF;
Transplantation; 2008 Apr; 85(8 Suppl):S57-60. PubMed ID: 18425038
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer screening in Tyrol, Austria: experience and results.
Horninger W; Reissigl A; Rogatsch H; Volgger H; Studen M; Klocker H; Bartsch G
Eur Urol; 1999; 35(5-6):523-38. PubMed ID: 10325519
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen in the assessment of organ donors.
Frutos MA; Daga D; Ruiz P; Jose Mansilla J; Requena MV
Transplant Proc; 2003 Aug; 35(5):1644-6. PubMed ID: 12962742
[TBL] [Abstract][Full Text] [Related]
10. Clinical Implication of Tests for Prostate-specific Antigen in Brain-dead Organ Donors.
Lee GW; Lee JM; Lee WJ; Kim YB; Min YG
Transplant Proc; 2018; 50(1):20-23. PubMed ID: 29407309
[TBL] [Abstract][Full Text] [Related]
11. Expanding the criteria of organ procurement from donors with prostate cancer: the application of the new Italian guidelines.
D'Errico-Grigioni A; Fiorentino M; Vasuri F; Corti B; Ridolfi L; Grigioni WF; ; Bagni A; Pirini MG; Malvi D; Fabbrizio B; Caprara G; Alvaro N
Am J Transplant; 2010 Aug; 10(8):1907-11. PubMed ID: 20659096
[TBL] [Abstract][Full Text] [Related]
12. [Is it convenient in a screening programme for prostate tumour to do biopsy in people with PSA between 3 and 3.9 ng/ml?].
Parravicini M; Del Boca C
Arch Ital Urol Androl; 2003 Jun; 75(2):99-101. PubMed ID: 12868147
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening.
Catalona WJ; Smith DS; Wolfert RL; Wang TJ; Rittenhouse HG; Ratliff TL; Nadler RB
JAMA; 1995 Oct; 274(15):1214-20. PubMed ID: 7563511
[TBL] [Abstract][Full Text] [Related]
14. Serial prostate specific antigen, free-to-total prostate specific antigen ratio and complexed prostate specific antigen for the diagnosis of prostate cancer.
Ellis WJ; Etzioni R; Vessella RL; Hu C; Goodman GE
J Urol; 2001 Jul; 166(1):93-8; discussion 98-9. PubMed ID: 11435831
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
Raaijmakers R; Wildhagen MF; Ito K; Pàez A; de Vries SH; Roobol MJ; Schröder FH
Urology; 2004 Feb; 63(2):316-20. PubMed ID: 14972481
[TBL] [Abstract][Full Text] [Related]
16. Role of PSA-related variables in improving positive ratio of biopsy of prostate cancer within serum PSA gray zone.
Liu B; Pan TJ
Urologia; 2014; 81(3):173-6. PubMed ID: 24557815
[TBL] [Abstract][Full Text] [Related]
17. [Estimating standard performance measures of opportunistic screening for prostate cancer].
Leoni M; Falcini F; Ravaioli A; Foca F; Andalò G; Benini F; Dal Pozzo C; Ricci R; Naldoni C; Bucchi L
Epidemiol Prev; 2008; 32(6):285-93. PubMed ID: 19353962
[TBL] [Abstract][Full Text] [Related]
18. Prostate specific antigen density of the transition zone for early detection of prostate cancer.
Djavan B; Zlotta AR; Byttebier G; Shariat S; Omar M; Schulman CC; Marberger M
J Urol; 1998 Aug; 160(2):411-8; discussion 418-9. PubMed ID: 9679889
[TBL] [Abstract][Full Text] [Related]
19. Opportunistic prostate-specific antigen screening in Italy: 6 years of monitoring from the Italian general practice database.
D'Ambrosio GG; Campo S; Cancian M; Pecchioli S; Mazzaglia G
Eur J Cancer Prev; 2010 Nov; 19(6):413-6. PubMed ID: 20679895
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer screening by prostate-specific antigen (PSA); a relevant approach for the small population of the Cayman Islands.
Jyoti SK; Blacke C; Patil P; Amblihalli VP; Nicholson A
Cancer Causes Control; 2018 Jan; 29(1):87-92. PubMed ID: 28918559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
